Nitisinone oral suspension regulatory update

FDA approved an NDA from Swedish Orphan for an oral suspension formulation of Orfadin nitisinone to treat hereditary tyrosinemia type I, a rare genetic disorder that can cause liver failure, kidney dysfunction and neurological problems. In August, the company plans to launch the new formulation of Orfadin, a synthetic reversible competitive inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD). ...